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Introduction. Percentage of galactose-deﬁcient IgA1 (Gd-IgA1) relative to total IgA in serum was recently reported to correlate
with proteinuria at time of sampling and during follow-up for pediatric and adult patients with IgA nephropathy. We sought to
determine whether this association exists in another cohort of pediatric patients with IgA nephropathy. Methods. Subjects were
younger than 18 years at entry. Blood samples were collected on one or more occasions for determination of serum total IgA
and Gd-IgA1. Gd-IgA1 was expressed as serum level and percent of total IgA. Urinary protein/creatinine ratio was calculated
for random specimens. Spearman’s correlation coeﬃcients assessed the relationship between study variables. Results. The cohort
had 29 Caucasians and 11 African-Americans with a male:female ratio of 1.9:1. Mean age at diagnosis was 11.7 ± 3.7 years.
No statistically signiﬁcant correlation was identiﬁed between serum total IgA, Gd-IgA1, or percent Gd-IgA1 versus urinary
protein/creatinine ratio determined contemporaneously with biopsy or between average serum Gd-IgA1 or average percent Gd-
IgA1 and time-average urinary protein/creatinine ratio. Conclusion. The magnitude of proteinuria in this cohort of pediatric
patients with IgA nephropathy was inﬂuenced by factors other than Gd-IgA1 level, consistent with the proposed multi-hit
pathogenetic pathways for this renal disease.
1.Introduction
IgAnephropathy(IgAN)isthemostcommonformofchron-
ic glomerulonephritis for individuals of European and Asian
descent [1, 2]. The level of proteinuria at diagnosis of IgAN
has been associated with the primary endpoint of outcome
(i.e., progression to chronic dialysis or transplantation) in
adults [3–7] and children [8–11].
Data from clinical and basic research in IgAN has led to
the hypothesis that four hits are responsible for clinical
expression of IgAN [12]. The ﬁrst hit is the presence of
aberrantly glycosylated O-linked glycans on the heavy-chain
hinge region of circulatory IgA1 that terminate in N-acetyl-
galactosamine (GalNAc) rather than galactose [13]. Elevated
serum levels of this galactose-deﬁcient IgA1 (Gd-IgA1) were
found in 76% of 153 Caucasian adults with IgAN in the
United States [14]. IgAN patients in Japan and China also
had elevated serum Gd-IgA1 levels [15, 16], as did African-
American patients in the southeastern United States [17]. In
addition, elevated serum Gd-IgA1 levels were found in 77%2 International Journal of Nephrology
of 22 African-American and Caucasian children with IgAN
[18].
The second hit is the induction of circulating IgG or IgA
antibodies speciﬁc for Gd-IgA1 [19], and the third hit is the
resultant formation of nephritogenic immune complexes
and their deposition in the glomerular mesangium. The ﬁnal
hit is the induction by these immune complexes of a local
proliferative and inﬂammatory response of the mesangial
cells [20–22]. Logically, the events related to the fourth hit
would be directly or indirectly responsible for the induction
of proteinuria in IgAN. In a recent study, the percentage of
serum Gd-IgA1 relative to serum total IgA1 was found to
correlate with proteinuria at time of sampling and over the
follow-up interval in 62 pediatric and adult patients [23].
Those data diﬀered from the ﬁndings at the time of sampling
in our initial report with adult patients [14]. The aim of the
present study was to determine whether the serum level of
Gd-IgA1 associates with proteinuria in a well-characterized
cohort of pediatric patients with IgAN.
2. Patientsand Methods
2.1. Study Population. T h es u b j e c t sh a db e e ne n t e r e di n t o
earlier studies approved by the Institutional Review Boards
of the University of Tennessee Health Science Center and
the University of Alabama at Birmingham. The diagnosis
of IgAN was established by renal biopsy showing IgA as
the dominant or codominant immunoglobulin in a typical
mesangial distribution, in the absence of clinical and lab-
oratory evidence for systemic disease [24] .A l ls u b j e c t sw e r e
younger than 18 years of age at the time of diagnostic biopsy.
This study did not enroll children who had received a kidney
transplant or who were on dialysis. Data for initial serum
Gd-IgA1 level were previously reported for 22 of the patients
included in the present report [17]. Of the 40 patients
in this study, 31 were diagnosed and followed up by the
pediatric nephrology group at the Le Bonheur Children’s
Hospital (LBCH) in Memphis, TN (LBCH cohort), ﬁve were
diagnosedatothercentersandseeninconsultationatLBCH,
two were diagnosed and followed in Lexington, KY, and two
in Birmingham, AL.
Serum samples were available from 97 healthy controls
younger than 18 years. The control group included 29
African-American males, 21 African-American females, 28
Caucasian males, and 19 Caucasian females.
2.2.LaboratoryMeasuresandDataCollection. Bloodsamples
were collected from patients on one or more occasions for
determination of serum total IgA, Gd-IgA1, and creatinine
concentration. Urinary protein and creatinine concentra-
tionsweremeasuredintheclinicallaboratoryfromarandom
spot urine sample, and a urinary protein/creatinine ratio
(UPCR) (g/g) was calculated. Estimated GFR was calculated
with the new Schwartz formula [25]. Systolic and diastolic
blood pressure percentiles based upon age, gender, and
height percentile were determined by the tables from the
Fourth Report on the Diagnosis, Evaluation, and Treatment
of High Blood Pressure in Children and Adolescents [26].
The blood pressure used for this calculation was the
average of available measurements within two months of
biopsy, if more than one was recorded. BMI percentile was
determined using the QuesGen Systems, Inc. web-based
calculator that used National Health and Nutrition Exam-
ination Survey data as the source for calculations (http://
www.quesgen.com/BMIPedsCalc.php).
Time-average (TA) proteinuria was determined accord-
ing to the description of Reich et al. [7], except that UPCR
was used instead of results of timed urine collections. The
UPCR was determined for each six-month interval after
biopsy; if there were two or more values for an interval, the
mean of the values was used. The TA-UPCR was derived
by averaging these UPCRs from each six-month interval of
follow-up time.
Serum total IgA and Gd-IgA1 levels were determined by
ELISA, as described previously [14]. The Gd-IgA1 ELISA
used biotinylated lectin from Helix aspersa (Sigma-Aldrich,
St. Louis, MO, USA) that binds speciﬁcally to terminal
GalNAc. Two galactose-deﬁcient IgA1 myeloma proteins,
McE and Ale, were used as standards in the Gd-IgA1
assays. Results for levels of Gd-IgA1 were expressed as U/mL
serum, with 1U (unit) corresponding to 1µgo fG d - I g A 1
myeloma standard protein. During the course of the study,
the standard in the assay was changed from McE to Ale; the
latter IgA1 myeloma protein has a slightly higher content
of terminal GalNAc. The McE standard had been used
exclusively for our initial reports [14, 17]. Subsequent levels
determined using the Ale standard were multiplied by a
factor of 2.5 to be compared to those determined in assays
using the McE protein as standard.
2.3. Statistical Analyses. The Mann-Whitney U test was used
to determine diﬀerences between patient and control groups
for serum levels of Gd-IgA1 and percent Gd-IgA1/IgA.
Spearman’s correlation coeﬃcients were used to assess the
relationship between study variables. SAS 9.1 (SAS Institute,
Cary, NC, USA) was used for descriptive statistics and
calculation of correlation coeﬃcients.
3. Results
Incident cases are deﬁned as those having a serum Gd-IgA1
level ﬁrst measured within 3 months after the diagnostic
biopsy. Prevalent cases had their ﬁrst Gd-IgA1 measurement
after longer intervals. Clinical and demographic data are
shown in Table 1 for the incident cases and in Table 2 for the
prevalent cases.
The LBCH cohort diﬀered from the other cases because
of higher percentages of African-Americans and subjects
with TA-UPCR determinations Table 3. The 40 patients
included 29 Caucasians and 11 African Americans; 26 were
male. For the IgAN group, the mean age ± SD at diagnosis
was 11.7 ± 3.7y e a r sa n d1 3 .2 ± 3.7 years at the time the ﬁrst
serum for Gd-IgA1 level was obtained. The mean ± SD age
at time of study was 12.6 ± 2.9 years for the healthy control
group.International Journal of Nephrology 3
Table 1: Clinical and demographic features of individual subjects (incident cases).
Subject Race/gender Presentation Age at estGFR Urinary protein/ BMI SBP/DBP Serum Gd-IgA1
biopsy (mL/min/1.73m2) creatinine ratio percentile percentile level (units/mL)
A1 C/M Microhematuria, 17.6 59 1.17 98 95–99/<50 262
proteinuria
M2 C/M Isolated proteinuria 13.8 78 1.24 26 95–99/50–90 889
M15 C/F Gross hematuria 11.2 80 1.31 <1 <50/50–90 1076
M16 C/F Gross hematuria 8.7 75 1.00 57 50–90/<50 1073
M17 C/M Gross hematuria 13.4 108 3.10 11 50–90/50–90 1534
M18 C/F Recurrent gross hematuria 12.5 107 2.96 17 >99/<50 1155
M19 AA/F
Gross hematuria,
15.9 49 2.97 52 <50, <50 3401 rapidly progressive
glomerulonephritis
M21 AA/M Isolated proteinuria 5.1 94 3.58 96 <50, 50–90 747
M22 C/M Gross hematuria, 8.6 75 1.33 49 95–99/50–90 803
acute kidney injury
M26 AA/M Gross hematuria 8.8 120 3.70 30 90–95/50–90 470
M28 C/F Gross hematuria, 16.7 63 1.36 40 90–95/50–90 1110
proteinuria
M29 C/M Gross hematuria 12.8 96 0.95 41 >99/95–99 659
M30 C/M Gross hematuria, 15.0 61 2.89 63 90–95/50–90 364
acute kidney injury
M31 C/M Gross hematuria 16.2 84 0.25 89 50–90/50–90 2513
T2 C/M
Microhematuria, proteinuria,
17.8 40 1.27 44 95–99/50–90 796 Chronic kidney
disease stage 3
AA: African-American; BMI: body mass index; C: Caucasian; estGFR, estimated glomerular ﬁltration rate; DBP: diastolic blood pressure; SBP: systolic blood
pressure; microhematuria, >5R B C / h i g hp o w e r e dﬁ e l d .
MeasurementsofserumGd-IgA1andUPCRonthesame
datewereavailableonatleastoneoccasionfor40patients;13
patients had from two to four paired samples over the course
of observation. A total of 62 paired samples for serum Gd-
IgA1 and UPCR were available for analysis.
The initial serum Gd-IgA1 levels for the patient and
control groups are shown in Figure 1(a).T h ep a t i e n tg r o u p
levels were signiﬁcantly higher than those of the control
group (P<0.0001). The median serum Gd-IgA1 level for
97 healthy controls under age 18 years was 260U/mL (inter-
quartile range (IQR) 183–334U/mL). Based upon these
controls, the 90th and 95th percentiles were 482U/mL and
645U/mL, respectively. For patients, median serum Gd-
IgA1 level was 688U/mL (IQR 517–1238U/mL) and the
median total serum IgA level was 2499U/mL (IQR 1930–
4072U/mL).
The initial medians for percent Gd-IgA1/total serum IgA
for the patient and control groups are shown in Figure 1(b).
The patient group levels were signiﬁcantly higher than those
of the control group (P<0.0001). The median percent Gd-
IgA1/total serum IgA level for 97 healthy controls under age
18 years was 17%, with an IQR of 10% to 22%. Based upon
these controls, the 90th and 95th percentiles were 32% and
34%, respectively. For patients, initial median percent Gd-
IgA1/totalserumIgAwas32%(IQR26%–48%).Themedian
UPCR was 0.74g/g (IQR 0.23–1.68g/g).
Spearman’s correlation coeﬃcients were also calculated
for serum Gd-IgA1, percent Gd-IgA1, age at biopsy, and
length of follow-up versus initial UPCR and TA-UPCR. For
patients having two or more measurements for serum Gd-
IgA1 and percent Gd-IgA1, the mean of these measurements
was used for the calculation of correlation coeﬃcients versus
TA-UPCR. Again, all correlations were determined to be
statistically insigniﬁcant and are as follows: serum Gd-IgA1
versus UPCR (r = 0.05, P = 0.72; Figure 2(a)), percent
serum Gd-IgA1 versus UPCR (r =− 0.11, P = 0.38;
Figure 2(b)), serum Gd-IgA1 versus TA-UPCR (r = 0.06,
P = 0.75; Figure 3(a)), percent serum Gd-IgA1 versus TA-
UPCR(r = 0.04,P = 0.87;Figure 3(b)),ageattimeofbiopsy
versus TA-UPCR (r = 0.18, P = 0.32), and length of follow-
up versus TA-UPCR (r = 0.10, P = 0.60). Of the 3 patients
who progressed to ESRD, all had TA-UPCR above 1.0 and
two had serum Gd-IgA1 levels above the 95th percentile for
healthy children.
UPCRandserumGd-IgA1levelswereplottedagainstage
for the subject with the longest period of serial serum Gd-
IgA1 sampling (Figure 4). This clinical course is of interest
in that the blood sample for measurement of the ﬁrst
level was obtained during an episode of gross hematuria
at time of diagnosis and the last three blood samples were
collected during clinical remission (urinalysis, UPCR and
serum creatinine concentration all normal).4 International Journal of Nephrology
Table 2: Clinical and demographic features of individual subjects (prevalent cases).
Subject Race/gender Presentation Age at estGFR Urinary protein/ BMI SBP/DBP Serum Gd-IgA1
biopsy (mL/min/1.73m2) creatinine ratio percentile percentile level (units/mL)
A2 AA/F Gross hematuria, 15.9 98 1.13 99 95–99/95–99 1320
proteinuria
A3 C/F Gross hematuria, 6.8 82 5.00 54 753
nephrotic syndrome
K1 C/M Gross hematuria 11.2 87 1.40 99 50–90/50–90 704
K2 C/M Microhematuria, 13.2 138 0.41 99 >99/50–90 919
proteinuria
M1 AA/M Microhematuria, 9.3 108 300mg/dL∗ 97 95–99/50–90 1328
proteinuria
M3 C/M
Isolated proteinuria,
13.0 50 4.12 95 95–99/50–90 594 chronic kidney disease
stage 3
M4 C/M Recurrent gross hematuria, 14.5 79 0.72 93 90–95/50–90 1867
acute kidney injury
M5 C/F Gross hematuria 11.6 79 3.61 61 95–99/50–90 363
M6 C/M Gross hematuria 11.6 98 255mg∗∗ 74 90–95/95–99 2177
M7 AA/F
Gross hematuria,
10.4 70 3.29 33 50–90/50–90 315 nephrotic syndrome,
acute kidney injury
M8 C/M Gross hematuria 17.4 67 0.44 94 90–95/50–90 1054
M9 C/M Recurrent gross hematuria 16.5 100 0.41 76 90–95/50–90 861
M10 AA/M Recurrent gross hematuria 7.0 102 0.64 90 95–99/50–90 563
M11 AA/F Gross hematuria 5.5 95 30mg/dL∗ 93 50–90/<50 882
M12 C/M Gross hematuria 8.5 87 0.04 15 50–90/50–90 612
AA: African-American; BMI: body mass index; C: Caucasian; estGFR: estimated glomerular ﬁltration rate; DBP: diastolic blood pressure; SBP: systolic blood
pressure.
∗Amount of protein by urinary dipstick;
∗∗Amount of protein in 24 hours.
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Figure 1: Serum levels of Gd-IgA1 plotted for the initial sample for 40 pediatric patients and 97 healthy pediatric controls. (a) Represented
as units/mL serum. Median is represented for each group. The serum level was signiﬁcantly higher for the patient group (P<0.0001). (b)
Represented as percentage of total IgA. Median is represented for each group by the red bar. The serum level was signiﬁcantly higher for the
patient group (P<0.0001).International Journal of Nephrology 5
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Figure 2: Random urinary protein/creatinine ratios. (a) Plotted against serum Gd-IgA1 levels. Spearman’s rank correlation is r = 0.05,
P = 0.72. (b) Plotted against percent Gd-IgA1 levels. Spearman’s rank correlation is r =− 0.11, P = 0.38.
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Figure 3: Time-average urinary protein/creatinine ratios. (a) Plotted against average serum Gd-IgA1 levels. Spearman’s rank correlation is
r = 0.06, P = 0.75. (b) Plotted against serum percent Gd-IgA1 levels. Spearman’s rank correlation is r = 0.04, P = 0.87.
4. Discussion
Remission of proteinuria is an important predictor of renal
survival. Analysis of 542 adult patients with IgAN in the
Toronto Glomerulonephritis Registry showed that when
treatment achieved a mean urinary protein excretion
<1g/day over the follow-up interval, the decline in glomeru-
lar ﬁltration rate was markedly slower than that for the
entire cohort [7]. Thus, magnitude of proteinuria is a useful
surrogate marker of outcome in IgAN patients detected early
in the course of disease when renal clearance function is
normal.
SerumGd-IgA1levelcanbeexpressedasanabsolutelevel
or as a percentage of total serum IgA. In our earlier cohort of
153 adults with IgAN, the absolute serum level was a better
diagnostic marker than percent Gd-IgA1, but neither Gd-
IgA1 (r =− 0.128, P = 0.211) [14]n o rp e r c e n tG d - I g A 1
(r =− 0.022, P = 0.788) (previously unpublished data)
correlated signiﬁcantly with UPCR. In that study, only
24 subjects were sampled within 8 weeks of biopsy for
measurement of the serum Gd-IgA1 level [14]. However, the
medianserumGd-IgA1levelforthose24subjectswassimilar
to the median for 26 subjects who had levels measured at the
last follow-up when the urinalysis and UPCR were normal.
In a Japanese cohort, however, there was no clinically
signiﬁcant diﬀerence in magnitude of proteinuria when sub-
jects over the age of 16 years were stratiﬁed by serum Gd-
IgA1 level above versus below the 90th percentile for healthy
controls [15]. The urine protein excretion for the 20 subjects
with serum Gd-IgA1 levels above the 90th percentile was
1.0g/day versus 1.1g/day for the 21 subjects with lower
serumGd-IgA1 levels. About 95% of the serumsamples used
for that study were obtained at the time of biopsy.
In a study by Camilla et al. [23], their cohort included
adults and children with IgAN and a correlation between
percent Gd-IgA1/IgA and contemporaneous UPCR was6 International Journal of Nephrology
Table 3: Clinical and demographic features of cohorts.
LBCH cohort Other Cases
n = 31 n = 9
Incident cases 13 2
Prevalent cases 18 7
Male 21 5
Female 10 4
Caucasian 21 8
African-American 10 1
Age at biopsy, yrs 11.5 ±4.71 2 .4 ±4.9
Follow-up after biopsy all 4.2 ±2.41 .9 ±2.0
p a t i e n t s ,y r s ,m e a n± SD
CKD5 at last follow-up 3 0
TA-UPCR data, patients 29 3
Follow-up after biopsy for 4.2 ±2.43 .1 ±2.1
TA-UPCR patients, yr, mean ± SD
TA-UPCR ≥ 1.0 9 1
TA-UPCR ≥ 0.5, < 1.0 7 0
TA-UPCR < 0.5 13 2
CKD5: chronic kidney disease stage 5; LBCH: Le Bonheur Children’s
Hospital; SD: standard deviation; TA-UPCR: time-average urinary pro-
tein/creatinine ratio; yrs: years.
0
0.5
1
1.5
2
U
r
i
n
e
 
p
r
o
t
e
i
n
/
c
r
e
a
t
i
n
i
n
e
 
r
a
t
i
o
8 1 01 21 41 61 8
Age (years)
0
500
1000
1500
S
e
r
u
m
 
G
d
-
I
g
A
1
 
l
e
v
e
l
 
(
u
n
i
t
s
/
m
L
)
Serum Gd-IgA1 level
Urine protein/creatinine ratio
Figure 4: Serum Gd-IgA1 levels (red circles) and concomitant
urinary protein/creatinine ratios are plotted for the patient having
the most serum Gd-IgA1 determinations. The red line represents
the 95th percentile for serum Gd-IgA level in healthy pediatric
controls, and the blue line represents the upper limit of normal for
urinaryprotein/creatinineratioof0.2.Thistimecourseisofinterest
in that the initial value was at presentation with gross hematuria
and the last three values were obtained during clinical remission
(normal urinalysis and estimated GFR).
found to be marginally signiﬁcant (r = 0.25, P = 0.03). The
correlation improved when TA-UPCR for each patient was
correlated against a single serum Gd-IgA1 level (r = 0.29,
P = 0.007). Our failure to conﬁrm this ﬁnding in a pediatric
cohort is not easily explained. A possible basis is a diﬀerence
in severity of disease. Our pediatric cohort had a higher
percentage of patients with low TA-proteinuria.
Serum Gd-IgA1 and percent Gd-IgA1 levels are often
elevated in ﬁrst-degree relatives of patients with IgAN [15,
27, 28]. However, virtually all of these aﬀected relatives had
noclinicalevidenceforrenaldiseaseprior tooratthetimeof
bloodsampling[15,27,28].Inaddition,carefulexamination
of the values for healthy controls indicates that serum Gd-
IgA1 levels are distributed in a nonparametric manner, such
that at least 5% of the subjects had a level higher than
predicted by a normal distribution [14, 15, 23].
Thus, the presence of serum Gd-IgA1 is necessary but
not suﬃcient to precipitate the renal injury in IgAN [12].
In the study of Suzuki et al. [19], levels of IgG speciﬁc for
Gd-IgA1 correlated with UPCR (P<0.0001) and with the
levels of IgA-IgG immune complexes normalized to urinary
creatinine (P = 0.0082) in contemporaneously collected
urine samples. This prognostic signiﬁcance may be due to
a requirement for the formation of immune complexes to
sustain renal injury in IgAN. The serum Gd-IgA1 level seems
tobemorevaluableasamarkerforriskofdiseaseratherthan
for prognosis [14].
5. Conclusion
In a cohort of pediatric patients with IgAN, we failed
to conﬁrm a recently described association between the
magnitude of proteinuria and percent serum Gd-IgA1/IgA
[21]. This ﬁnding is similar to that in our initial North
American cohort and a Japanese cohort of adults [14, 15].
Thus, the weight of the evidence to date fails to support a
relationship between the serum Gd-IgA1 level and severity
of proteinuria. This clinical expression of disease in IgAN
is likely inﬂuenced by other factors or hits, such as levels
of circulating antibodies speciﬁc for Gd-IgA1, level and/or
composition of Gd-IgA1-containing immune complexes, or
other factors that inﬂuence mesangial inﬂammation.
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